Ebola vaccine shows T cell cross-reactivity against Bundibugyo virus in humans

This announcement comes amid the second largest Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo, which has resulted in over 6,000 confirmed cases and a 48% fatality rate. The current Ebola vaccine has been found to induce T cell cross-reactivity against the Bundibugyo virus in humans, despite there being no approved vaccine specifically for BDBV.

Originally published by gnews